1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Global Clinical Trials Review, H2, 2015

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, “Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Global Clinical Trials Review, H2, 2015" provides an overview of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) clinical trials scenario. This report provides top line data relating to the clinical trials on Mucopolysaccharidosis I (MPS I) (Hurler Syndrome). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Global Clinical Trials Review, H2, 2015
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) to Metabolic Disorders Clinical Trials 15
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) to Metabolic Disorders Clinical Trials 19
Clinical Trials by Phase in E7 Countries 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials 29
Prominent Drugs 31
Clinical Trial Profile Snapshots 32
Appendix 63
Abbreviations 63
Definitions 63
Research Methodology 64
Secondary Research 64
About GlobalData 65
Contact Us 65
Disclaimer 65
Source 66

List of Tables
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials by Region, 2015* 6
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 10
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, North America, Top Countries, 2015* 12
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 13
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 14
Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2015* 16
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 18
Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2015* 20
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 21
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials by Phase, 2015* 22
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 23
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 24
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 25
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 26
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 27
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 28
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 30
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 31

List of Figures
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials by Region (%), 2015* 6
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 10
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12
Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2015* 15
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 18
Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2015* 19
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 21
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials by Phase (%), 2015* 22
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 23
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 24
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 25
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 26
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 27
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 28
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 29
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 31
GlobalData Methodology 64

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Mucopolysaccharidosis-Market Insights, Epidemiology and Market Forecast-2023

Mucopolysaccharidosis-Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Mucopolysaccharidosis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...

Hyperparathyroidism - Market Insights, Epidemiology and Market Forecast-2023

Hyperparathyroidism - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Hyperparathyroidism - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...

Hyperthyroidism - Market Insights, Epidemiology and Market Forecast-2023

Hyperthyroidism - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Hyperthyroidism - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.